Last reviewed · How we verify
Chlorophyllin
Chlorophyllin is a Small molecule drug developed by Tata Memorial Centre. It is currently in Phase 2 development. Also known as: Stratum A (Symptomatic), Stratum A (Asymptomatic).
Chlorophyllin is a semi-synthetic derivative of chlorophyll, commonly used as a food additive and in alternative medicine. It has been studied in clinical trials for various conditions, including Hidradenitis Suppurativa, high blood glucose, and uterine cervical neoplasm, but its exact mechanism of action is unknown.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Chlorophyllin |
|---|---|
| Also known as | Stratum A (Symptomatic), Stratum A (Asymptomatic) |
| Sponsor | Tata Memorial Centre |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Iron Absorption From Plant Heme Iron (NA)
- A Clinical Trial to Assess the Effectiveness of NRF2 Activator (Oral Sodium-copper- Chlophyllin ) in Locally Advanced Cervical Cancer to Reduce Late Radiotherapy Toxicity. (PHASE3)
- Efficacy and Safety of Alcovit in Reducing Blood Alcohol Concentration (NA)
- SCRT in TNT With or Without Chlorophyllin (PHASE2)
- A Study of Chlorophyllin for the Management of Brain Radio-necrosis in Patients With Diffuse Glioma (PHASE2)
- Effects of Sulforaphane for Patients With Chronic Kidney Disease (NA)
- BSE on Blood Glucose (NA)
- The Effects of Mirtoselect®, Virtiva®, and Enovita® on Cognitive Performance and Mood States (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Chlorophyllin CI brief — competitive landscape report
- Chlorophyllin updates RSS · CI watch RSS
- Tata Memorial Centre portfolio CI
Frequently asked questions about Chlorophyllin
What is Chlorophyllin?
Who makes Chlorophyllin?
Is Chlorophyllin also known as anything else?
What development phase is Chlorophyllin in?
Related
- Manufacturer: Tata Memorial Centre — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: Stratum A (Symptomatic), Stratum A (Asymptomatic)
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing